Episode 71

On this week’s Biotech Hangout, guest Frank David, Tufts Professor & Author, joins Daphne Zohar, Chris Garabedian, Dawn Bell and Brian Skorney to discuss the latest biotech news. Following recent news from several “Hub & Spoke” companies, including raises from Apollo, Nimbus & Star Therapeutics, the hosts discuss this innovative business model. They also cover M&A news, including the FTC’s approval of Amgen’s acquisition of Horizon Therapeutics and Nestle’s decision to sell the peanut allergy drug it acquired for $2.6B for an undisclosed upfront payment. Other big topics include the 10 drugs announced for Medicare negotiations. Additional themes include the IPO landscape from the ECM, private and crossover perspectives, CymaBay data, Applied Therapeutics FDA meeting & implications for orphan diseases, and Tonix Pharmaceuticals’ data. *This episode aired on September 8, 2023